Science Pool

Understanding BMS-986094 Cardiotoxicity using Human iPSC-Derived Cardiomyocytes

BMS-986094 (INX-08189) is a guanosine nucleotide analogue prodrug which was developed to treat hepatitis C virus (HCV). However, BMS-986094 was discontinued in Phase III clinical trials with 1 death and 8 people hospitalised with significantly reduced left ventricular ejection fraction (LVEF). Cardiotoxic effects were observed in 14 out of the 34 patients with left ventricular dysfunction, with ST depressions, T-wave inversions or loss of T-wave amplitude.

In this poster, we focus on:

  • investigating the mechanism behind the cardiotoxicity of BMS-986094
  • the use of MEA and human iPSC-derived cardiomyocytes in long term incubations with BMS-986094

Read our poster to learn more about our research!

Sounds interesting?
Enter your details below to continue reading…

By clicking on ‘Continue’ I agree that my data is being transferred to the Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our Privacy Policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below:

Join our community

Discover the exclusive benefits on offer if you join our community.